3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Melphalan
4
Irinotecan
4
Filgrastim
4
Cyclophosphamide
4
Busulfan
4
fludarabine
3
Topotecan
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
pegfilgrastim
2
liposomal doxorubicin
2
Thiotepa
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
ribociclib
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
olaparib
1
mocetinostat
1
lexatumumab
1
irinotecan sucrosofate
1
fludarabine phosphate
1
cixutumumab
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled